logo

Biolinerx Ltd. (BLRX)



Trade BLRX now with
  Date
  Headline
5/11/2022 7:25:43 AM BioLineRx Q1 Net Loss $4.9 Mln Vs Loss Of $10.2 Mln Last Year
3/16/2022 7:09:55 AM BioLineRx FY Net Loss $27.1 Mln Vs Loss $30.0 Mln Last Year
1/18/2022 7:06:00 AM BioLineRx Completes Pre-NDA Meeting With FDA For Motixafortide For Stem Cell Mobilization In Multiple Myeloma Patients
12/17/2021 7:10:28 AM BioLineRx Reports Successful Phase 3 Trial Of Motixafortide Plus G-CSF For Stem Cell Mobilization In Multiple Myeloma
11/18/2021 7:13:41 AM BioLineRx Q3 Net Loss Widens To $5.7 Mln, From $4.6 Mln Prior Year
11/4/2021 9:17:52 AM BioLineRx Announces An Oral Presentation And Three Poster Presentations
10/13/2021 8:32:39 AM BioLineRx Reports Positive Results From Study Positioning Motixafortide As Standard Of Care In Stem Cell Mobilization
8/18/2021 7:18:55 AM BioLineRx Reports Q2 Net Loss Of $6.8 Mln Same With Last Year
5/26/2021 7:15:53 AM BioLineRx Q1 Loss Per Share $0.02 Vs Loss $0.04 Last Year
5/4/2021 7:21:14 AM BioLineRx Announces Positive Top-Line Results From GENESIS Phase 3 Trial Of Motixafortide
4/15/2021 7:25:42 AM BioLineRx Says On Track To Report Final Data From Phase 3 GENESIS Trial Of Motixafortide
2/23/2021 7:18:00 AM BioLineRx FY Net Loss $30.02 Mln Vs. Net Loss $25.5 Mln Last Year